Ewing Sarcoma Market is Expected to Showcase a Significant Growth by 2032 | DelveInsight

New York, USA, March 29, 2023 (GLOBE NEWSWIRE) — Ewing Sarcoma Market is Expected to Showcase a Significant Growth by 2032 | DelveInsight

The Ewing sarcoma market is predicted to grow positively owing to the anticipated launch of therapies such as Vigil, Eribulin mesylate during the forecast period, i.e., 2023–2032. Moreover, widespread research and developmental activities of pharmaceutical companies, along with rising incidence, will further fuel the growth of the Ewing sarcoma market.

DelveInsight’s Ewing Sarcoma Market Insights report includes a comprehensive understanding of current treatment practices, Ewing sarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Ewing Sarcoma Market Report

• As per DelveInsight analysis, the Ewing sarcoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• As per the assessment by DelveInsight, throughout the study period, an increasing trend in the incident cases of Ewing’s sarcoma is expected to occur in the US.
• Leading Ewing sarcoma companies such as Gradalis, Eisai, Salarius Pharmaceuticals, Tyme, Jazz Pharmaceuticals, Pfizer, Eli Lilly and Company, Cellectar Biosciences, Inc., Valent Technologies, LLC, Sumitomo Pharma Oncology, Inc., Bristol-Myers Squibb, Ono Pharmaceuticals, Nektar Therapeutics, Inhibrx, Inc., and others are developing novel Ewing sarcoma drugs that can be available in the Ewing sarcoma market in the coming years.
• Some of the key therapies for Ewing sarcoma treatment include Vigil EWS, Eribulin mesylate, Seclidemstat, SM-88, Lurbinectedin, CP-751,871, Abemaciclib, CLR 131, VAL-413, TP-1287, Nivolumab, Bempegaldesleukin, INBRX-109, and others.
• The emerging therapeutics options in the Ewing sarcoma treatment landscape are focusing on novel targets.

Discover which therapies are expected to grab the major Ewing sarcoma market share @ Ewing Sarcoma Market Report

Ewing Sarcoma Overview

Ewing’s sarcoma, also known as peripheral primitive neuroectodermal tumor, Askin tumor, extraosseous Ewing sarcoma, and the Ewing sarcoma family of tumors, is a type of malignant tumor that begins in the bone. It primarily affects children and young adults, and it is most common during the adolescent years. Except for a mismatch in genetic material on chromosomes 11 and 22, the cause of Ewing’s sarcoma is unknown. At the tumor site, there is usually pain and possibly swelling. Conversely, the tumor may be present for months before it becomes large enough to cause pain and swelling. The presence of a mass is sometimes the first Ewing sarcoma symptom.

After discussing symptoms, a physical examination is performed to confirm the Ewing sarcoma diagnosis. X-rays, MRI scans, CT scans, and bone scans are preferred imaging tests. A biopsy is performed to confirm the presence of any tumor. Following tumor identification, cancer staging is determined by additional tests such as blood tests, CT scans of the lungs, bone scans, and bone marrow biopsy.

Ewing Sarcoma Epidemiology Segmentation

Among the 7MM, EU5 has a significant number of Ewing’s sarcoma as the estimated incidence is considered to be 1.5 per million among people of European descent. The lowest incident population of Ewing sarcoma was recorded in Japan as compared to the US and EU5.

The Ewing sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Ewing Sarcoma Incident Cases
• Ewing Sarcoma Age-Specific Cases
• Ewing Sarcoma Subtype-specific Cases
• Ewing Sarcoma Treatable Cases
• Ewing Sarcoma Gender-Specific Cases

Download the report to understand which factors are driving Ewing sarcoma epidemiology trends @ Ewing Sarcoma Epidemiological Insights

Ewing Sarcoma Treatment Market 

The Ewing sarcoma treatment is primarily determined by where it is located in the body and how far it has spread when it is discovered. Vincristine, doxorubicin, ifosfamide, and etoposide are always included in multidrug chemotherapy for Ewing sarcoma. Most protocols also include cyclophosphamide and, in some cases, actinomycin. The mode of administration and dose intensity of cyclophosphamide within courses varies significantly across protocols. According to the European Intergroup Cooperative Ewing Sarcoma Study (EICESS), 1.2 g of cyclophosphamide produced a similar event-free survival (EFS) compared to 6 g of ifosfamide in patients with lower-risk disease, and there was a trend toward better EFS for patients with localized Ewing sarcoma and higher-risk disease when treatment included etoposide.

Ewing sarcoma treatment approaches and therapeutic aggressiveness must be adjusted to maximize local control while minimizing morbidity. The most common method of local control is surgery. In cases where the functional or cosmetic morbidity of surgery is deemed too high by experienced surgical oncologists, radiation therapy is an effective alternative modality for local control. However, in the immature skeleton, radiation therapy can result in deformities that are more morbid than surgical deformities. Postoperative radiation therapy is indicated when complete surgical resection with pathologically negative margins cannot be obtained.

To know more about Ewing sarcoma treatment, visit @ Ewing Sarcoma Treatment Drugs 

Key Ewing Sarcoma Therapies and Companies

• Vigil EWS: Gradalis
• Eribulin mesylate: Eisai
• Seclidemstat: Salarius Pharmaceuticals
• SM-88: Tyme
• Lurbinectedin: Jazz Pharmaceuticals
• CP-751,871: Pfizer
• Abemaciclib: Eli Lilly and Company
• CLR 131: Cellectar Biosciences, Inc.
• VAL-413: Valent Technologies, LLC
• TP-1287: Sumitomo Pharma Oncology, Inc.
• Nivolumab: Bristol-Myers Squibb/Ono Pharmaceuticals
• Bempegaldesleukin: Bristol Myers Squibb/Nektar Therapeutics
• INBRX-109: Inhibrx, Inc.

Learn more about the FDA-approved drugs for Ewing sarcoma @ Drugs for Ewing Sarcoma Treatment 

Ewing Sarcoma Market Dynamics

The dynamics of the Ewing sarcoma market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2022─2032. In addition, leading companies all over the globe are persistently working towards the development of new treatment therapies, which will further propel the Ewing sarcoma market growth. 

Overall, the outcome of Ewing sarcoma has improved due to the tremendous efforts of researchers and clinicians all over the world, improved liaison between all stakeholders of the treating team, and collaborative international research in a large number of cases. The main challenge now is to prevent a recurrence, drug resistance, reduce therapy-related long-term toxicities, and improve outcomes in patients with metastatic and relapsed/recurrent disease. So far, no potential biomarker has been identified to predict the therapeutic efficacy of chemotherapeutic agents or recurrences. The future hope lies in the discovery of useful biomarkers, a better understanding of disease biology and chemotherapy resistance in Ewing sarcoma cells, the proper design and execution of targeted therapies currently in clinical trials, and the improved use of high throughput methods to detect novel driver mutations/pathways and potential targets.

Furthermore, the Ewing sarcoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Ewing sarcoma market growth.

Scope of the Ewing Sarcoma Market Report

• Therapeutic Assessment: Ewing Sarcoma current marketed and emerging therapies
• Ewing Sarcoma Market Dynamics: Attribute Analysis of Emerging Ewing Sarcoma drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Ewing Sarcoma Market Access and Reimbursement

Discover more about Ewing sarcoma drugs in development @ Ewing Sarcoma Clinical Trials

Table of Contents

Related Reports

Ewing Sarcoma Epidemiology Forecast

Ewing Sarcoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Ewing sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Ewing Sarcoma Pipeline

Ewing Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Ewing sarcoma companies, including Sumitovant Biopharma, Velicept Therapeutics, Taiho Pharmaceutical, Dong-A ST Co., Ltd., Bayer, among others.

Osteosarcoma Market

Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies including Y-mAbs Therapeutics, Jiangsu Hengrui Medicine, AstraZeneca, Advenchen Laboratories LLC, among others.

Soft Tissue Sarcoma Pipeline

Soft Tissue Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key soft tissue sarcoma companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, among others.

Clear Cell Sarcoma Pipeline

Clear Cell Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, among others.

Osteosarcoma Epidemiology Forecast

Osteosarcoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted osteosarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Ewing Sarcoma Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs

Osteosarcoma vs. Ewing Sarcoma

Ewing Sarcoma Market Landscape

Osteosarcoma Treatment Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter